CymaBay Therapeutics Inc (NASDAQ:CBAY) has today made the much awaited announcement. The ongoing low-dose Phase 2 study of seladelpar was conducted in a bid to develop top solutions to help persons struggling with primary biliary cholangitis (PBC).This is a severe life-limiting chronic cholestatic liver complication. It goes without saying that the positive interim results obtained marks a major step forward in the medical field.
This particular study involved a number of patients at high risk of disease progression. They showcased inadequate response to ursodeoxycholic acid (UDCA) and each of them was served with a 5 mg or 10 mg of seladelpar each passing day.
An interim analysis was carried out and it involved a total of 24 patients. After 12 weeks, the researchers observed a conspicuous AP reduction. Some reliable sources place it at a baseline between 39% and 45% for those administered with the 5 mg and 10 mg groups.
As a matter of fact, AP stands out distinctly as the surrogate marker. This is of course in line with the disease progression in PBC and goes way up to a level of < 1.67 x ULN. It is the major component in the composite endpoint that is crucial when experts want to arrive at the regulatory approval.
In making his reports, the lead researcher outlined, “Alongside substantial reductions in AP, patients in both dose groups experienced decreases in other liver markers of cholestasis including gamma glutamyl transferase and total bilirubin. Seladelpar also improved metabolic and inflammatory markers with patients experiencing decreases in low-density lipoprotein-C and high sensitivity C-reactive protein.”
One thing that stood out clearly was the fact that no serious adverse effects were experienced. It is also crucial to outline that the researchers did not also observe any safety transaminase signal for any of the doses under study. The progression of the study witnessed a major decrease in the mean transaminase levels. This added weight to the seladelpar’s anti-inflammatory activity.
The data obtained from the study has been termed by experts as quite impressive. It has strongly supported the hypothesis set up for the study. Lower doses of seladelpar do not pose any danger of transaminase elevations according to Yahoo.
